2 terminated, 1 withdrawn. 2 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 2 | Terminated 2 |
Follow Gateway Biotechnology, Inc.: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Noise-Induced Hearing Loss-Acute Exposure Treatment (UA) Zonisamide 100Mg Cap, Placebo - Hearing Loss, Noise-Induced | Phase 2 | Terminated | Washington University School of Medicine | 3 | 2021-11-10 | 2026-02-13 |
| Noise-Induced Hearing Loss-Acute Exposure Treatment Zonisamide 100Mg Cap, Placebo - Hearing Loss, Noise-Induced | Phase 2 | Terminated | Washington University School of Medicine | 24 | 2021-10-04 | 2025-01-15 |
| Hearing Changes After Surgery Distortion product otoacoustic emissions (DPOAE) - Hearing Loss | Withdrawn | Gateway Biotechnology, Inc. | 2021-09-01 | 2022-08-09 |
Hearing Loss, Noise-Induced (2) · Hearing Loss (1)
Capsules (2) · Zonisamide (2) · microcrystalline cellulose (2) · Acoustic Impedance Tests (1) · Audiometry (1)
United States (3)
Craig A Buchman, MD, FACS (2) · Partha Thirumala, MD (1)
R41DC017406 (1)